Abstract
There is an extensive evidence that corticotropin releasing factor (CRF) is hypersecreted in depression and anxiety, and blockade of CRF could have therapeutic benefit. We report preclinical data and the results of a clinical Phase I study with the novel nonpeptide CRF1 antagonist NBI-34041/SB723620. Preclinical data conducted with different cell lines expressing human CRF receptors and in Wistar and Sprague–Dawley rats indicate that NBI-34041 is effective in reducing endocrine responses to pharmacological and behavioral challenge mediated by CRF1 receptors. These specific properties and its well-documented safety profile enabled a clinical Phase I study with 24 healthy male subjects receiving NBI-34041 (10, 50, or 100 mg) or placebo for 14 days. Regulation of the hypothalamic–pituitary–adrenocortical (HPA) axis was evaluated by intravenous stimulation with 100 μg of human CRF. Psychosocial stress response was investigated with the Trier Social Stress Test (TSST). Treatment with NBI-34041 did not impair diurnal adrenocorticotropic hormone (ACTH) and cortisol secretion or CRF evoked ACTH and cortisol responses but attenuated the neuroendocrine response to psychosocial stress. These results suggest that NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress. NBI-34041 demonstrates that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Aguilera G, Nikodemova M, Wynn PC, Catt KJ (2004). Corticotropin releasing hormone receptors: two decades later. Peptides 25: 319–329.
Arzt E, Holsboer F (2006). CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol Sci 27: 531–538.
Britton KT, Lee G, Dana R, Risch SC, Koob GF (1986). Activating and ‘anxiogenic’ effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 39: 1281–1286.
Chalmers DT, Lovenberg TW, De Souza EB (1995). Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15: 6340–6350.
de Kloet ER, Joels M, Holsboer F (2005). Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6: 463–475.
Dickman SJ (2002). Dimensions of arousal: wakefulness and vigor. Hum Factors 44: 429–442.
Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P et al (1984). Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 141: 619–627.
Grigoriadis DE (2005). The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 9: 651–684.
Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW et al (1996). 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol 50: 679–686.
Gross RS, Guo Z, Dyck B, Coon T, Huang CQ, Lowe RF et al (2005). Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. J Med Chem 48: 5780–5793.
Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (2003). International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55: 21–26.
Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, Chalmers DT (1997). Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71: 15–21.
Held K, Kunzel H, Ising M, Schmid DA, Zobel A, Murck H et al (2004). Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 38: 129–136.
Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW et al (2001). Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol Psychiatry 6: 540–546.
Holsboer F (2003). Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 4: 46–50.
Holsboer F, Muller OA, Doerr HG, Sippell WG, Stalla GK, Gerken A et al (1984a). ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression. Psychoneuroendocrinology 9: 147–160.
Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Muller OA (1984b). Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 311: 1127.
Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005). The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 1085–1093.
Kirschbaum C, Pirke KM, Hellhammer DH (1993). The ‘Trier Social Stress Test’—a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76–81.
Kunzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A et al (2005). Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 39: 173–177.
Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A et al (2003). Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37: 525–533.
Laux L, Glanzmann P, Schaffner P, Spielberger CD (1981). The State-Trait Anxiety Inventory (STAI). Beltz: Weinheim, Germany.
Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F (1999). Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33: 153–163.
Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M et al (1995). Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59: 229–239.
McCarthy JR, Heinrichs SC, Grigoriadis DE (1999). Recent progress in corticotropin-releasing factor receptor agents. In: Robertson DW (ed). Annual Reports in Medicinal Chemistry. Academic Press: San Diego, CA. pp 11–20.
Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO et al (2004). Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24: 1478–1485.
Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P et al (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100–1107.
Nemeroff CB, Bissette G, Akil H, Fink M (1991). Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158: 59–63.
Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988). Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45: 577–579.
Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K et al (1984). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342–1344.
Pepin MC, Pothier F, Barden N (1992). Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 355: 725–728.
Perrin MH, Vale WW (1999). Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 885: 312–328.
Rossier J, French ED, Rivier C, Ling N, Guillemin R, Bloom FE (1977). Foot-shock induced stress increases beta-endorphin levels in blood but not brain. Nature 270: 618–620.
Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW (1987). CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 144: 641–645.
Ruch W (1999). The revised version of the Eysenck Personality Questionnaire and the development of the German version of the EPQ-R and EPQ-RK. Zeitschrift für Differentielle und Diagnostische Psychologie 20: 1–24.
Sanchez MM, Young LJ, Plotsky PM, Insel TR (1999). Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408: 365–377.
Saunders J, Williams J (2003). Antagonists of the corticotropin releasing factor receptor. Prog Med Chem 41: 195–247.
Skelton KH, Owens MJ, Nemeroff CB (2000). The neurobiology of urocortin. Regul Pept 93: 85–92.
Skutella T, Probst JC, Renner U, Holsboer F, Behl C (1998). Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 85: 795–805.
Spielberger CD, Gorsuch RL, Lushene RE (1996). State-Trait-Anxiety Inventory Selfrating scale. In: Collegium Internationale Psychiatriae Scalarum (CIPS) (ed). Internationale Skalen für Psychiatrie. Beltz: Göttingen, Germany. pp 27–30.
Steckler T, Dautzenberg FM (2006). Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence—an update. CNS Neurol Disord Drug Targets 5: 147–165.
Strohle A, Poettig M, Barden N, Holsboer F, Montkowski A (1998). Age- and stimulus-dependent changes in anxiety-related behaviour of transgenic mice with GR dysfunction. Neuroreport 9: 2099–2102.
Wittchen HU, Zaudig M, Fydrich T (1997). SCID. Structured Clinical Interview for DSM-IV. Hogrefe: Göttingen, Germany.
Zimmermann U, Spring K, Kunz-Ebrecht SR, Uhr M, Wittchen HU, Holsboer F (2004). Effect of ethanol on hypothalamic-pituitary-adrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacology 29: 1156–1165.
Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M et al (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171–181.
Zorrilla EP, Koob GF (2004). The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13: 799–828.
Acknowledgements
The work described in this paper was supported by Neurocrine Biosciences Inc., San Diego, CA, USA, and by GlaxoSmithKline, Research Triangle Park, NC, USA. Allan C Foster and Dimitri E Grigoriadis are employees of Neurocrine Biosciences Inc. (NBI). Susan Learned-Coughlin is an employee of GlaxoSmithKline (GSK).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Ising, M., Zimmermann, U., Künzel, H. et al. High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response. Neuropsychopharmacol 32, 1941–1949 (2007). https://doi.org/10.1038/sj.npp.1301328
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301328
Keywords
This article is cited by
-
Sex as a biological variable in stress and mood disorder research
Nature Mental Health (2023)
-
Synthesizing Chiral Drug Intermediates by Biocatalysis
Applied Biochemistry and Biotechnology (2020)
-
Region-specific roles of the corticotropin-releasing factor–urocortin system in stress
Nature Reviews Neuroscience (2016)
-
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436
Psychopharmacology (2016)
-
Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm
Psychopharmacology (2013)
